Member Info for 1DayRodney

@amin0406
I hope you realise my reply was somewhat tongue-in-cheek :)

Like I said yesterday, it's gonna take something special to get this really moving but today's RNS is a welcome update.

Don't be so impatient.
If the we get top results from the 25ton sample, it could burst it's way to 4p!
;)

@roger65

Are you related to Marvin?

https://youtu.be/CAA67a2-Klk

Lol.

Hoping so...

It's been nearly a year since the SP crushing technical report was released and despite the interviews, q&a and later 'revised' presentation, this stock has remained stubbornly suppressed and stagnant.

It's gonna need to be a humdinger of an RNS to get this sloth moving!

Not sure where the £1.10 comes from (?) but the £80 price quoted is the the final price to the NHS.
GDR won't get near that when you account for distributor margin, packaging & manufacturing cost etc.
The machines themselves will provide the initial revenue, along with any support/maintenance contracts.

But AIHL's real winning attribute is that it gets us a foot in the door with the NHS, European healthcare institutes and, eventually (hopefully!) the USA.
Once that foot's in the door, future assays will be readily received and we'll also become that bit shinier for the Pharma Magpies.

Does anyone know how we would stand if we are on the right side of the Bacanora royalty ownership challenge judgement in Alberta but the Mexican government manage to wrestle the mining rights away from Gangfeng and give it to state owned LitioMx?

I was wondering how they put in the shop windows too...

The LSE share trades list is pants.. my buy shows as a sale :S

I agree. It doesn't make sense in my mind either.

Riverfort would need to sell @ 30.77 just to break even on the first 2million tranche without any guarantee of profit or that GDR make any further drawdowns.
Warrants are not a guarantee of profit. In fact in this case, GDR would need growth for Riverfort to benefit.

For those that maybe unaware, 2 RNS were issued late Friday.

One is the half yearly report, the other is about a £5million equity facility.

For those who are invested, the equity facility will be subject to a shareholder vote at a General Meeting (date not yet confirmed)

So are you saying our new investor may be corrupt as stated by the speaker in your video link?
I think you need to be careful MR.

BTW even with my rosy goggles on, even I know the most important thing now is sales, sales, sales!

I've re-read the funding RNS a couple of times since issue.
I've only got a few AIM companies in my portfolio and I've not dealt with one of these facilities before. It's timings plus the fact that it is a drawdown facility rather than a lump sum piqued my interest.

Here's a few of my ambling thoughts..

The initial drawdown of £2m takes the company to exactly the point in time at which they expect certifications, initial marketing and NICE approval for the stroke assay plus completion of initial 'proper' sales of AIHL. It also represents a comparatively smaller initial dilution of approx 7%, rather than the approx 17% a conventional share raise for the same (but one off) £5m potentially would have done.

The monthly withdrawal limit of £300k ensures the company doesn't fritter away the money all in one go (as best possible anyways).

The 2yr finance term is also structured in such a way that the BOD almost seem to also have one eye on either:

¦ Not needing to ever fully drawing down the facility within the term and letting it expire (enough sales to support company, make a profit and cover development instead within the period)

¦ Paying back the facility early before fully drawing down (again reason as above)

¦ A substantial takeover offer being put on the table effectively making the facility a minimally absorbed debt (at whatever level of drawdown it currently would be).

If anywhere near the predicted level of sales (even 20%!) were to be achieved within the 2yr term, then this finance facility will become effectively irrelevant especially if not fully realised.

Then again, my analysis could be complete pants and I'm probably looking at it incorrectly through future wishing rosy glasses!

@Samberox

The Genedrive kit is a comparison study with another POC (as mentioned in the RNS) and conventional lab test.
The NICE timetable and all documentation can be found here.
Next scheduled date is 18th of this month which is a committee meeting.

https://www.nice.org.uk/guidance/indevelopment/gid-dg10054

It's my understanding trials maybe running concurrently in Scotland.

@Guy (0737)

That's a daft thing to say.
How can perpetuating an unassured investor base possibly help the company?
Investors need reassurance and a clear mapped out path to growth.

Selling of the AIHL test in the UK is Inspiration Healthcare's job. They are the designated sales & distributor.
It will be Genedrive's job to provide customer support and training.

That's last year's report which allows the NHS to use the test.
The report we are waiting to be published is the one that says the use of the test is 'best practice' i.e. near enough compulsory.

*one or two trick pony

Don't forget we already have the POC covid and HCV assays at commercial stage and available to purchase plus Tuberculosis (MTB/RF) assay has also gone back into development.
This aint no one orcteo trick pony :)

I think so..
Nowadays, acquisitions are probably the safer and cheaper way for the big boys to expand rather than initially develop and market new products themselves.

Concentrate on the message rather than the semantics.
A share is just the smallest denomination or an individual unit of a stock. My inkling is neither will exist...happy?